Antibody response to a T-dependent antigen requires B cell expression of complement receptors by unknown
Antibody Response to a T-dependent Antigen Requires 
B  Cell Expression of Complement Receptors 
By Denise A. Croix,* Joseph M. Ahearn,* Ariella M. tLosengard,* 
Shuhua Hanfl Garnett Kelsoefl Minghe Ma,II  and Michael C. Carrollll 
From the *  Graduate Program in Immunology and the Division of Molecular and Clinical 
Rheumatolo~, the Department of Medicine, the Department of Molecular Biology and Genetics, and 
the t Department vf Pathology,  Johns Hopkins School of Medidne, Baltimore, Maryland 
21205- 2196; the S  Depatlment of Microbiology and Immunology, School of Medicine, University of 
Maryland, Baltimore, Maryland 21201-1559;  and the JlDepartment of Pathology, Harvard Medical 
School, Boston, Massachusetts 02I 15 
Summary 
Several  lines  of evidence indicate  that  antibody responses  to T-dependent  antigens  require 
complement receptors expressed on either B lymphocytes or follicular dendritic cells. We have 
used RAG-2--deficient blastocyst  complementation to create  mice specifically lacking B  cell 
complement receptors.  Despite normal expression  of complement receptor 1 (CI~1  [CD35]) 
and CR2 (CD21) on follicular dendritic cells, these mice have a profound defect in their ca- 
pacity to mount a T-dependent antibody response. This is the first direct demonstration in vivo 
that B  cell expression  of complement receptors is required for a humoral immune response. 
This suggests that CD21 and/or CD35 on B lymphocytes may be required for cellular activa- 
tion,  adsorptive endocytosis of antigen,  recruitment  to germinal  centers,  and/or protection 
from apoptosis during the humoral response to T-dependent antigens. 
A~ 
tical role for the complement system in generating 
tibody responses  to T  cell-dependent  (TD)  1 anti- 
gem  was first  suggested  more  than  20 years  ago  by the 
demonstration that in vivo depletion of complement pro- 
tein C3 with cobra venom factor suppressed  the antibody 
response of  mice to SRBCs (1-3). The capacity of C5- and 
C6-deficient animals to mount normal antibody responses 
and the impaired responses (including  absent secondary re- 
sponses and isotype switching)  of humans,  guinea pigs, and 
dogs genetically  deficient in C2, C4, or C3 suggested  that 
the effect of cobra venom factor was the direct result of C3 
deficiency (for review see reference 4). More recent studies 
have determined that the in vivo antibody response  to TD 
antigens  can be inhibited  by administration  of either the 
anti-complement  receptor mAb 7G6  (5-7),  or a  soluble 
form  of CR2  (8)  before immunization.  Together,  these 
observations  have identified the interaction of complement 
receptors with hgands derived from C3 as a critical point at 
which the immune and complement systems intersect. 
In  mice,  expression  of complement  receptor  2  (CR2 
[CD21]) (Fig. 1) is limited to B cells and follicular dendritic 
cells (FDCs).  This observation has generated two principal 
tAbbreviations used in this  paper: ES, embryonic  stem; FDC, follicular  den- 
dritic cell; MCP,, murine complement receptor; NP, 4-hydroxy-3-nitro- 
phenyl acetyl; SCR., short consensus  repeat; TD, T cell-dependent. 
hypotheses to explain  the critical role of the C3--CK2 in- 
teraction during TD antibody responses. First, immune com- 
plexes bearing C3 hgan& may act directly on B lympho- 
cytes.  The  capacity  of C3-derived ligands  to stimulate  B 
cell growth and activation is thought to occur through coh- 
gation  of CR2,  which participates  with  CD19,  TAPA-1, 
and Leu-13 in a B cell--specific complex (9), and the anti- 
gen receptor, membrane IgM. Cross-linking  CD19 to IgM 
on B cells lowers the number of antigen receptors required 
for inducing DNA synthesis by two orders of magnitude 
(10),  and  signals transduced  through  this  complex  have 
been shown to trigger  recruitment of phosphatidylinositol 
kinase  (11), augment  activation  of phospholipase C  (12), 
and enhance cellular adhesion (13). In vivo, this coligation 
is thought to result from antigen and/or antigen-antibody 
complexes bearing iC3b and/or C3dg as a result of activat- 
ing  the  classical and/or  alternative  pathways  of comple- 
ment. 
The second potential site at which a C3-CR2 immuno- 
modulatory event might  occur is at the surface of FDCs, 
unique APCs that play a major role in trapping  and pre- 
serving  native antigens  within peripheral  lymphoid tissue 
(for review see reference 14). After primary immunization, 
immune complexes activate complement, and these antigerr- 
Ab-C3 complexes traffic to FDCs, where they are captured 
by C3 receptors.  It has been demonstrated that C3 is essen- 
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Volume 183 April 1996 1857-1864 Figure  1.  Structure  and  function  of routine  CRs  (29--33). Murine 
CIL1 (MCIL1, CD35) and murine  CtL2 (MCR2,  CD21),  alternative 
transcripts of the Cr2 gene, are cell surface glycoproteins that specifically 
recognize proteolytic fragments of complement components C3 and C4. 
MCtL1, M  t 190,000, is expressed by B cells, FDCs, peritoneal macro- 
phages, and activated geanulocytes and serves to bind C3b, iC3b, C3d, 
and C4b.  MCR2,  Mr 150,000, is expressed by B cells and FDCs and 
serves to bind iC3b and C3d. MCR.2 has an extracellular domain com- 
posed entirely of 15 short comemus repeats (SCRs), a 27-amino  acid 
transmembrane region, and a 35-residue cytoplasmic  tail. The structure of 
MCtL1 is identical to that of MCR.2, except for the presence of an addi- 
tional six SCP,.s at the amino terminus that contain a binding domain for 
C3b, C4b, and mAb 8C12. SCIL-1 and SCIL-2 of MCP,2,  which are 
common  to both receptors, mediate binding of iC3b,  C3d,  and mAb 
7G6, which blocks binding of  both ligands to the receptors. 
tial for targeting of TD antigens to murine lymphoid folli- 
cles and for the subsequent development of memory B  cells 
(15,  16).  The  undegraded antigen that is captured and re- 
tained by FDCs is thought to provide the stimulus for the 
formation of germinal centers. This antigen depot may also 
provide a necessary stimulus for the generation and perpet- 
uation  of memory B  cells through  continued  stimulation 
without additional administration of antigen (17). Thus, the 
immunomodulatory effect of a C3-CR~2 interaction might 
be  via localization and  retention  of C3-bearing  immune 
complexes  on  the  reticulum  of CR1-  and  CR2-bearing 
cytoplasmic processes of FDCs.  These studies were under- 
taken to  characterize the antibody response to  a  TD  anti- 
gen in mice specifically deficient in B  cell CR.1  and C1~2 
and thereby to dissect the relative contributions to humoral 
immunity of complement receptors expressed on B  cells as 
compared with those on FDCs. 
Materials and Methods 
Creation of  Mice with CD21- and CD35-dtyldent B Cells.  The  tar- 
geting vector used in these studies was assembled from a 6.5-kb 
fragment of the Cr2 gene that was isolated from a genomic library 
prepared from the 129 mouse strain (Fig. 2). The genomic DNA 
was subcloned into the plasmid pNT, which bears a neo selection 
marker under control of  the PGK promoter. The murine Cr2 gene 
was disrupted through insertion of  the neo gene into a BamHI site 
within the coding region for SCtL-10 ofmurine complement re- 
ceptor (MCIL)2, which introduces a frameshifc and a stop codon, 
resulting in disruption of MCtkl and MCR2 expression. 2  ￿  107 
embryonic stem  (ES) cells (cell line ABI, originated by Dr.  A. 
Bradley, Baylor College of Medicine, Houston, TX) were tram- 
fected by electroporation with  20  p,g of linearized pNT.CtL2, 
were plated onto five 10-cm dishes coated with Sto feeder cells 
(treated with  mitomycin  C  to  prevent  cell division), were  al- 
lowed to recover for 6 h, and were cultured for 6 d in double se- 
lection medium  (0.5  mg/ml  G418  and 2.0  I~M gancyclovir in 
DMEM  supplemented  with  recombinant  leukemia  inhibitory 
factor and 15% FCS). 250 colonies were grown to confluence in 
96-well plates that were coated with feeder cells. Genomic DNA 
was prepared from them, and targeted clones were screened for 
identification of positives as described (18).  DNA samples were 
digested with BamHI and analyzed by Southern blot hybridiza- 
tion. A cDNA probe was used that recognizes an 8-kb fragment 
within the wild-type Cr2 gene, which is expected to increase to 
10 kb after incorporation of the targeting vector. After primary 
screening, eight positives were identified, each of which was ex- 
panded and  further  analyzed in  secondary screening.  All eight 
were heterozygous for the disrupted Cr2 allele, and six of these 
had a normal number of 40 chromosomes (data not shown). One 
of these clones was cultured for 14 d in 3 mg/ml G418 selection 
medium to obtain a clone homozygous for the 02  null allele. 10 
colonies were picked and screened by Southern blot analysis to 
identify clones  homozygous for  the  Cr2-disrupted allele. One 
clone  harboring homozygous  disruption  of the  Cr2  locus was 
identified,  expanded,  and  used  for microinjection of RAG-2- 
deficient embryos as described (19, 20). 
Flow Cytomet~.  Splenic mononuclear cells were obtained by 
layering through Ficoll-Paque (Pharmacia Biotech, Inc., Piscat- 
away, NJ) and were washed with PBS, 2% BCS,  10 mM Hepes, 
0.01% sodium azide. For each sample, 5  ￿  10  s  to 1  ￿  106 cells 
were  used for flow cytometric analysis.  Cells were sequentially 
incubated with  biotinylated anti-mouse  CtL1/CR2  mAb  7E9 
followed by avidin-PE and FITC-conjugated anti-mouse CD19 
mAb  1D3  and were  analyzed on a  FACScan  |  flow cytometer. 
Data analysis was performed with the Consort 30 program. Shown 
are the results of at least 50,000 events analyzed for each sample. 
Iramunohistochemistry.  Spleens were snap frozen in OCT (Bio- 
media, Foster City, CA) cooled in liquid nitrogen. Frozen sec- 
tions (5--6 p,m) were thaw-mounted and stored at -20~  Sec- 
tions were fixed either in 4% formaldehyde for 6  min at room 
temperature  (CD19,  CR.1/2)  or in  acetone for  10  rain at 4~ 
(CD3, 4-hydroxy-3-nitrophenyl  acetyl [NP]), rehydrated in PBS, 
incubated in normal goat (CD19, CIL1/2) or rabbit (CD3, NP) 
serum for 20 min at room temperature, and were incubated for I  h 
at room temperature with rat anti-mouse CD19  mAb 1D3,  rat 
anti-mouse  CR1/CR2  mAb  7G6,  hamster  anti-mouse  CD3 
mAb 500A2, or NIPs-BSA. Sections incubated with rat or ham- 
ster mAbs were incubated with biotinylated rabbit Ab specific for 
rat Ig or biotinylated goat Ab specific for hamster immunoglobu- 
lin, respectively. All sections were  subsequently incubated with 
avidin-biotin complex for 30 min at room temperature, incubated 
with  diaminobenzidine substrate  (brown)  (Vector Laboratories, 
Burlingame, CA) for 5 min at room temperature, counterstained 
with  hematoxylin,  dehydrated,  and  mounted  with  Permount 
(Fischer Scientific, Fair Lawn, NJ). 
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murine Cr2 locus encodes both MCR1 and MCIL2, which 
are generated by alternative splicing (22, 23). Shown from 
top to bottom are partial restriction maps of the mouse Cr2 
genomic locus, the targeting vector in which the neo gene 
has been inserted at a BamHI site within the exon encoding 
SCR.-10 of mouse CR.2, and the anticipated result of suc- 
cessful targeting of the locus. H, HinDIII; B, BamHI; X, 
Xho I. (B) DNA samples  were digested  with BamHI and an- 
alyzed by Southern blot hybridization. A cDNA probe  was 
used that recognizes  an 8-kb fragment  within the wild-type 
Cr2 gene which is expected to increase to 10 kb a~er incor- 
poration of the targeting vector. Shown are the results of 
Southern blot hybridization of an ES cell line that is het- 
erozygous (lane 2) and one that is homozygous (lane 3) for 
Cr2 disruption. 
ELISA.  ELISAs were performed by coating microtiter wells 
with 100 ~  NP-KLH (50 ~,g/ml) in 0.1 M NaHCO 3 pH 9.8, at 
4~  followed by sequential incubations  with sera diluted in bo- 
vine lactotransfer technique optimizer (BLOTTO)-Tween, goat 
anti-mouse IgG-AP conjugate,  and substrate. Plates were read at 
OD4o5. 
Results and Discussion 
We have taken advantage of the RAG-2 blastocyst com- 
plementation  experimental  system  developed  by Alt  and 
colleagues  (21)  to  determine  that  expression  of comple- 
ment receptors by murine B cells is specifically required for 
humoral  immunity.  RAG-2-deficient  mice  are  homozy- 
gous for the null allele at the RAG-2 locus, which results in 
failure to form mature T  and B lymphocytes, but are other- 
wise normal (22).  This defect can be corrected by microin- 
jection  of embryos  with  ES  cells  that  contain  a  normal 
RAG-2  allele.  However,  if the  ES  cells  that  are  used  to 
complement  the  deficient  embryos  are  homozygous  for 
some  other  null  allele,  it  becomes  possible  to  study  the 
functional effects of this specific mutation in T  and B lym- 
phocytes without affecting other tissues  directly.  Thus,  all 
mature lymphocytes must be homozygous for the specific 
mutation being studied,  because they can  only arise from 
the  injected ES  cells,  whereas  all  other  tissues  are poten- 
tially chimeric. 
We have created ES cells homozygous for targeted dis- 
ruption of the Cr2 gene (which encodes both murine com- 
plement receptors CR.1  [CD35] and CR2 [CD21]) and in- 
jected  these  Cr2-deficient  ES  cells  into  R.AG-2--deficient 
blastocysts  to  generate  mice  with  a  B  cell-specific  deft- 
ciency of complement receptors  (Fig.  2).  If RAG-2-defi- 
cient mice are reconstituted with normal ES cells,  the off- 
spring  should  express  complement  receptors  on  both  B 
lymphocytes and FDCs. In contrast, RAG-2-deficient mice 
reconstituted with  ES  cells  homozygous for disruption  of 
the  Cr2  locus  should  express  complement  receptors  on 
FDCs, but all mature B  cells should be complement recep- 
tor negative. 
We first determined whether mature B  cells  in the  tar- 
geted mice were deficient in surface expression of CR1 and 
CK2. Splenic mononuclear cells were prepared and assayed 
for reactivity with the B  cell marker CD19 and for expres- 
sion  of complement receptors as determined by reactivity 
with  mAb  7E9,  which  binds  to  an  epitope  common  to 
both murine CtL1  and CR2 (see Fig.  1). As shown in Fig. 
3, most CD19-positive cells derived from a BALB/c mouse 
also express  complement receptors,  whereas mononuclear 
cells purified from the spleen of a RAG-2-deficient mouse 
demonstrate total deficiency of  mature CD19-positive B cells. 
If a RAG-2-deficient mouse is reconstituted with normal 
ES cells, mature splenic B cells reappear in normal numbers 
with a CD19-positive, complement receptor-positive phe- 
notype. However, when Cr2-deficient  ES cells are used for 
blastocyst complementation, mature CD19-positive B  cells 
populate  the  spleen,  but  they  are  complement  receptor 
negative, as expected. 
As  shown  in  Table  1,  the  numbers  of CD19-positive 
splenic B  cells and the numbers of CD3-positive splenic B 
cells  observed in  the  CR.2-deficient mice ranged from 29 
to  55%  and  23  to  40%,  respectively,  slightly  below  the 
numbers observed in the normal controls. Complement re- 
ceptors were detected on 37-55% of the spleen cells in the 
normal mice, which was nearly identical to the percentages 
of cells that expressed CD19. In contrast, splenic mononu- 
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Figure  3.  How  cytometric 
analysis of splenic mononuclear 
ceils. Single  splenic mononuclear 
cell suspemiom were prepared 
and  assayed for  expression of 
CD19 and CR1/CP,2  by dual 
color flow cytometric analyses. 
(A),  wild-type BALB/c, (B), 
RAG=2-defident, (Q, ILAG-2- 
deficient reconstituted  with nor- 
mal ES calls, and (D) RAG-2- 
deficient  recomtituted  with 
Cr2--deficient ES  cells. Shown 
are the results of at least 50,000 
events, analyzed  for each sample. 
clear cells from the targeted mice were consistently com- 
plement receptor negative.  Significant quantities of all  Ig 
isotypes studied were detectecl in each of the experimental 
mice;  however,  the  levels  of several  subclasses,  such  as 
IgG2a  and  IgG2b,  were markedly lower in  the  comple- 
ment receptor-deficient animals. 
Mice reconstituted with Cr2-deficient cells and control 
mice reconstituted with normal ES cells were immunized 
intraperitoneally with 10 Izg of NP-KLH in alum at days 0 
and 21.  All mice were killed on day 28,  at which time 
antibody responses to  the  immunogen were  determined. 
RAG-2-deficient mice  that had been reconstituted with 
normal ES ceils generated anti-NP titers (Table 1) similar 
to those seen with normal mice (data not shown). In con- 
trast,  RAG-2-deficient mice that had been reconstituted 
with Cr2-deficient ES cells generated no detectable antibody 
response to the  hapten NP  as measured by ELISA using 
NP-BSA. When the antibody response to NP-KLH was 
measured by ELISA using NP-KLH, the titers observed in 
control mice were again similar to those of  wild-type mice, 
whereas mice lacking B cell expression of complement re- 
ceptors were  unable  to  generate  significant antibody re- 
sponses (Fig. 4). 
Immunohistochemic,l  studies  were  performed  on  the 
spleens of all mice in an attempt to further understand the 
cellular  basis  for  this  failure  of humoral  immunity.  As 
shown  in  Fig.  5,  CD19  expression in  C1L  +/+  mice was 
limited almost exclusively to the peripheral or B cell region 
of the foUicles, sparing the central T  cell zone, a pattern 
nearly identical to that observed for expression of comple- 
ment receptors. As observed with the control mice, CD19 
expression was limited to the  peripheral B  cell region of 
CR -/- mice. In striking contrast with the pattern observed 
with normal mice, expression of complement receptors in 
the spleem of the targeted mice did not parallel CD19 ex- 
pression. Instead, we observed an intense reticular pattern 
1860  Failure  of Humoral Immunity in Complement Receptor-deficient Mice Table 1.  Characterization of the Immune Response to NP-KLH by CR  +/+ and CR  -/- Mice 
Percentage of cells positive 
for expression  of 
Serum levels of lg isotypes 
Anti-NP  CD19 +  Splenic mononuclear 
Mouse  titer  CD3  CD19  CIL1/CR2  CR1/CR2  IgM  IgG1  IgG2a  IgG2b  IgG3  IgA  cells 
Izg/ml  ￿  106 
Ctk +/+ 1  70,000  31  48  47  43  900  2,400  1,400  500  450  1,640  13.6 
CR.  +/+ 2  3,000  34  56  54  49  510  1,350  5,200  600  530  1,940  13.6 
CIL  +/+ 3  70,000  33  61  55  52  700  1,500  1,800  500  640  1,860  12.1 
CR  +/+ 4  3,000  44  42  37  38  700  620  1,220  125  340  1,340  2.7 
CR.  -/- 1  0  38  55  1  1  400  800  920  100  230  1,640  3.4 
CR.  -/- 2  0  29  39  0  0  950  400  480  40  230  790  7.9 
CR -/- 3  0  40  46  0  0  600  250  580  100  215  1,080  8.8 
Ctk -/- 4  0  23  29  0  0  225  3,500  950  60  300  226  9.5 
Each of  four Ctkl/CR2 +/+ mice and each of  four CRI/CR2 -/- mice was immunized with 10 ~g of  NP-KLH in alum on days 0 and 21. On day 
28, all mice were killed and assayed for serum levels oflg isotypes, serum titers oflgG anti-KLH, total numbers of  splenic mononuclear cells, and 
percentages of  splenic mononuclear cells positive for surface expression of either CD3, CD19, or CR1/CR2, or positive for coexpression of CK1/ 
CR2 and CD19. 
of staining of cells with anti-CR.1/CP,.2 mAb 7E9 in a lim- 
ited  peripheral  area  of the  follicle.  This  pattern  was  ob- 
served in splenic follicles of all  Cr2-deficient mice,  consis- 
tent  with  expression  of complement  receptors  limited  to 
3 
f_ 
8 
"1 
.,  ........  ,  ........  ,  ........  ,  0 
10 =  10 s  10 4  10 +  10  e 
Serum Dilution 
Figure 4.  Immune response to NP-KLH. ILAG-2-deficient mice re- 
constituted with normal ES cells (0) and ILAG-2-deficient mice recon- 
stituted with Cr2-deficient ES cells (O) were immunized intraperitoneally 
with 10 g,g NP-KLH in alum on day 0 and on day 21. Mice were killed 
on day 28, at which time serum titers to NP-KLH were determined by 
ELISA. Mice complemented with normal ES cells generate titers compa- 
rable to those observed a~er immunization of wild-type mice (data not 
shown), whereas no significant anti-NP-KLH response was observed in 
mice lacking B cell expression of  complement receptors. 
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FDCs.  Further  identification  of these  complement recep- 
tor-bearing  cells  as  FDCs was achieved by demonstrating 
their  reactivity  in  serial  sections  with  the  FDC-specific 
mAb FDC-M1, which produced the same staining pattern 
(data not shown). 
Although the flow cytometric studies indicated  that the 
experimental  mice  had  somewhat  decreased  numbers  of 
CD3-positive  splenic  mononuclear cells,  no apparent  dif- 
ferences  in number  or distribution  were  detected  by im- 
munohistochemistry (Fig. 5). 
Finally, the spleens of all mice were assayed for reactivity 
with NP-BSA to identify antibody-forming B cells.  Spleens 
of all  control  mice  were  filled  with  numerous  intensely 
positive  NP-reactive  B  cells,  located  primarily  in  the  red 
pulp. In contrast, although NP-positive cells were detected 
in the spleens of all immunized complement receptor-defi- 
cient mice, they were consistently far fewer, and their reac- 
tivity with NP-BSA was much less  intense  than  was  ob- 
served in the spleens of control mice. 
Together,  these findings demonstrate that mice express- 
ing  complement  receptors  on  FDCs  but  lacking  B  cell 
CR1  and  CR.2  generate  insignificant  antibody  responses 
after immunization  with NP-KLH.  However,  these mice 
are  capable  of generating  NP-specific  B  cells,  suggesting 
that their immune response is profoundly impaired,  rather 
than absolutely deficient.  There appear to be at least four 
explanations for the essential role played by B  cell comple- 
ment receptors during generation of antibodies to TD anti- 
gens. First, as described above, immune complexes that ac- 
tivate  complement  may  stimulate  B  cell  activation  and 
proliferation  by triggering  signals  transduced  through  the 
CtL2-CD19 membrane complex (9).  Recent observations 
that CD 19-deficient mice exhibit a similarly profound deft- Figure  5.  [mmunohistochemical  analysis of  mouse 
spleens.  Spleens  from  RAG-2--deficient mice recomtitoted 
with normal ES  cells (CK  +/§  (A,  C,  E,  G,  and  /)  and 
KAG-2-deficient  mice  reconstituted  with  CKt/CP..2- 
deficiem ES ceils (CB.  -/-) (B, D, F, H, and J) were assayed 
for expression  of CD19  (.4  and  B),  CK1/2  (C and  D), 
CD3 (E and F) and for the presence ofND-specific B cells 
(G-J).  Kepresentative  serial sectiom demonstrate 
distributiom  of  CD19-positive (.4) and complement recep- 
tor--positive (C) cells in the spleen of a CK  +/+ mouse.  In 
striking contrast, serial sectiom from the spleen ofa CIL  -/- 
mouse demonstrate  normal expression  of CD19 in the B 
cell regions (B), with complement receptor expression lim- 
ited to FDCs within a limited peripheral area of the follicle 
(/9). As shown at lower (C and H)  and  higher (I and J) 
magnifications,  numerom  NP-reactive  cells, presumably 
NP-specitic B cells, were observed in the spleem of CK  */+ 
mice, primarily in the red pulp (G and/-/). In contrast, al- 
though  hiP-reactive cells were present  in the spleem  of 
CK  -/- mice, they were more diflScult to find (H and J). 
No reactivity with NP-BSA was observed in the spleem of 
normal mice that were not immunized (data not shown). 
The numbers  and distribution  of CD3-positive ceils were 
comparable in CK  +/+ (E) and CK  -/- (F) mice. (A and C') 
X80; (B, D, E, F, G, and/-/) X128; (land.I)  X320. 
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ports that at least one role of  B cell complement receptors is 
mediated through this pathway (23,  24).  Second,  comple- 
ment  receptors  may provide a  mechanism for B  cell ad- 
sorptive  endocytosis  of antigen,  which  is  then  processed 
and presented to T  cells  during development of germinal 
centers. Third, B cells that have been activated extrafollicu- 
larly may depend upon complement receptors for their re- 
cruitment to peripheral lymphoid follicles, where they in- 
teract with antigen that has been trapped by FDCs. Fourth, 
positive  selection  of antigen-specific  B  cells  in  germinal 
centers is dependent upon their ability to bind antigen and 
survive apoptosis. C3-derived ligands may provide a bridge 
between  complement  receptors  expressed  on  FDCs  and 
those expressed on B  cells,  facilitating this interaction.  Al- 
ternatively,  it  may be  that  B  cell  complement  receptors 
must  interact  with  CD23,  a  ligand  for  CR.2  that  is  ex- 
pressed at high levels on a subset of FDCs  (25-28);  how- 
ever, this  alone does not  explain the known requirement 
for C3 in the process. 
This experimental system can now be expanded to dis- 
tinguish  the  relative  contributions  of murine  CR1  and 
CR2  to the humoral immune response, by reconstituting 
null mice differentially with each receptor, respectively. It 
should  also  be possible to rescue the immune response of 
these deficient mice with B  cell-specific expression of mu- 
tant receptors, such as those lacking the domains that have 
been identified as critical for interaction with C3,  CD19, 
and CD23.  This will enable further definition and dissec- 
tion of the roles of complement and complement receptors 
during generation of a humoral immune response. 
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